Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 7/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21447140 | 0.92 | MKNK2 (0.37) | CRHR1MKNK2 | |
| SCHEMBL21447122 | 0.88 | MKNK2 (0.35) | CRHR1MKNK2KDR | |
| SCHEMBL21447295 | 0.86 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL21447176 | 0.81 | CRHR1 (0.37) | CRHR1 | |
| SCHEMBL19952874 | 0.81 | CRHR1 (0.48) | CRHR1GAA | |
| SCHEMBL21447121 | 0.81 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL21447164 | 0.77 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL21447293 | 0.77 | CRHR1 (0.37) | CRHR1 | |
| SCHEMBL21447162 | 0.75 | MAPK1 (0.35) | CRHR1MAPK1 | |
| SCHEMBL21447167 | 0.75 | CRHR1 (0.38) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077108-B2 | Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-03 | — | — | US | disclosed |
| US-20190307747-A1 | ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077108-B2 | Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition | CRHR1, CRH, CRHR2 | CRHR1 1/4885MKNK2 2832/4885FGFR1 401/4885 |
| US-20190307747-A1 | ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION | CRHR1, CRH, CRHR2 | CRHR1 1/4885MKNK2 1330/4885FGFR1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.